Streptococcus pneumoniae Vaccination in Older Adults

Elizabeth Rightmier PharmD , Vanessa Stevens PhD , Jack Brown PharmD, MS
{"title":"Streptococcus pneumoniae Vaccination in Older Adults","authors":"Elizabeth Rightmier PharmD ,&nbsp;Vanessa Stevens PhD ,&nbsp;Jack Brown PharmD, MS","doi":"10.1016/j.amjopharm.2011.09.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><em>Streptococcus pneumoniae</em> infections are a major cause of morbidity and mortality in older adults. Vaccination in older adults is intended to prevent <em>S pneumoniae</em> infections, yet little information is available regarding its efficacy in this patient population.</p></div><div><h3>Objective</h3><p>The aim of this article was to review the current literature to determine the efficacy and tolerability of <em>S pneumoniae</em> vaccination in older adults.</p></div><div><h3>Methods</h3><p>PubMed (1950–present) and EMBASE (1974–present) were searched using the search terms <em>Streptococcus pneumoniae immunization, pneumococcus immunization, pneumococcus vaccine</em>, and <em>aged</em>. Additional articles were identified from the reference lists of included studies. Studies were included if they reported information in older (55–&lt;65 years) and elderly (≥65 years) adults and were related to at least 1 of the following topics: epidemiology of <em>S pneumoniae</em>, estimates of vaccine coverage, recommendations for vaccination, tolerability, and efficacy and/or effectiveness of vaccination against <em>S pneumoniae.</em></p></div><div><h3>Results</h3><p>Six randomized controlled trials and 18 observational studies that evaluated the efficacy of pneumococcal vaccination in older and elderly adults were reviewed. Findings from evaluations of efficacy, as measured by clinical outcomes and immunogenicity, in older adults have been conflicting, with some subsets of prospective, well-controlled studies finding little benefit, whereas findings from several retrospective studies have suggested significant benefit. This discord may have been a result of the limited power of the prospective subanalyses to detect significant differences.</p></div><div><h3>Conclusions</h3><p>In light of the potential clinical benefit and few reports of serious adverse events, vaccination in older adults is likely warranted. Prospective, well-controlled studies are needed to better quantitatively evaluate the benefit of pneumococcal vaccine in older adults.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"9 6","pages":"Pages 392-404"},"PeriodicalIF":0.0000,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2011.09.008","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal Geriatric Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S154359461100170X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

Background

Streptococcus pneumoniae infections are a major cause of morbidity and mortality in older adults. Vaccination in older adults is intended to prevent S pneumoniae infections, yet little information is available regarding its efficacy in this patient population.

Objective

The aim of this article was to review the current literature to determine the efficacy and tolerability of S pneumoniae vaccination in older adults.

Methods

PubMed (1950–present) and EMBASE (1974–present) were searched using the search terms Streptococcus pneumoniae immunization, pneumococcus immunization, pneumococcus vaccine, and aged. Additional articles were identified from the reference lists of included studies. Studies were included if they reported information in older (55–<65 years) and elderly (≥65 years) adults and were related to at least 1 of the following topics: epidemiology of S pneumoniae, estimates of vaccine coverage, recommendations for vaccination, tolerability, and efficacy and/or effectiveness of vaccination against S pneumoniae.

Results

Six randomized controlled trials and 18 observational studies that evaluated the efficacy of pneumococcal vaccination in older and elderly adults were reviewed. Findings from evaluations of efficacy, as measured by clinical outcomes and immunogenicity, in older adults have been conflicting, with some subsets of prospective, well-controlled studies finding little benefit, whereas findings from several retrospective studies have suggested significant benefit. This discord may have been a result of the limited power of the prospective subanalyses to detect significant differences.

Conclusions

In light of the potential clinical benefit and few reports of serious adverse events, vaccination in older adults is likely warranted. Prospective, well-controlled studies are needed to better quantitatively evaluate the benefit of pneumococcal vaccine in older adults.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
老年人肺炎链球菌疫苗接种
背景肺炎链球菌感染是老年人发病和死亡的主要原因。老年人接种疫苗的目的是预防肺炎链球菌感染,但关于其在这一患者群体中的有效性的信息很少。目的回顾目前的文献,以确定老年人肺炎链球菌疫苗接种的疗效和耐受性。方法采用肺炎链球菌免疫、肺炎球菌免疫、肺炎球菌疫苗、年龄等检索词对spubmed(1950 -至今)和EMBASE(1974 -至今)进行检索。从纳入研究的参考文献列表中确定了其他文章。如果研究报告了老年人(55 - 65岁)和老年人(≥65岁)的信息,并且与以下主题至少1项相关:肺炎链球菌流行病学、疫苗覆盖率估计、疫苗接种建议、耐受性、疫苗接种的有效性和/或有效性。结果回顾了6项随机对照试验和18项观察性研究,评估了老年人和老年人肺炎球菌疫苗接种的疗效。以临床结果和免疫原性衡量的疗效评估结果在老年人中存在矛盾,一些前瞻性、对照良好的研究亚组发现几乎没有益处,而一些回顾性研究的结果表明有显著益处。这种不一致可能是由于前瞻性亚分析检测显著差异的能力有限。结论鉴于潜在的临床益处和严重不良事件的报道较少,老年人接种疫苗可能是有必要的。需要前瞻性、对照良好的研究来更好地定量评估老年人接种肺炎球菌疫苗的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American Journal Geriatric Pharmacotherapy
American Journal Geriatric Pharmacotherapy GERIATRICS & GERONTOLOGY-PHARMACOLOGY & PHARMACY
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
Author Index Subject Index Editorial Board Adverse Effects of Analgesics Commonly Used by Older Adults With Osteoarthritis: Focus on Non-Opioid and Opioid Analgesics Effect of Combination Fluticasone Propionate and Salmeterol or Inhaled Corticosteroids on Asthma-Related Outcomes in a Medicare-Eligible Population
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1